MeSH Browser

MeSH Heading: Dideoxyadenosine
Tree Number(s): D03.633.100.759.590.138.325.105; D13.570.230.229.105; D13.570.230.500.105; D13.570.583.138.325.105
Unique ID: D016048
RDF Unique Identifier: http://id.nlm.nih.gov/mesh/D016048
Annotation: an antiviral; inhibits HIV replication
Scope Note: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is an inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal side effect is nephrotoxicity. In vivo, dideoxyadenosine is rapidly metabolized to DIDANOSINE (ddI) by enzymatic deamination; ddI is then converted to dideoxyinosine monophosphate and ultimately to dideoxyadenosine triphosphate, the putative active metabolite.
Entry Term(s): 2',3'-Dideoxyadenosine; ddA (Antiviral)
Pharm Action: Antimetabolites
Antiviral Agents
Related Numbers: 4097-22-7
CAS Type 1 Name: Adenosine, 2',3'-dideoxy-
Previous Indexing: Deoxyadenosine/analogs & derivatives (1975-1989); Dideoxynucleosides (1989)
Public MeSH Note: 90
History Note: 90
Date Established: 1990/01/01
Date of Entry: 1989/07/14
Revision Date: 2016/05/31

Allowable Qualifiers: administration & dosage (AD)

adverse effects (AE)

agonists (AG)

analogs & derivatives (AA)

analysis (AN)

antagonists & inhibitors (AI)

blood (BL)

cerebrospinal fluid (CF)

chemical synthesis (CS)

chemistry (CH)

classification (CL)

economics (EC)

history (HI)

immunology (IM)

isolation & purification (IP)

metabolism (ME)

pharmacokinetics (PK)

pharmacology (PD)

poisoning (PO)

radiation effects (RE)

standards (ST)

supply & distribution (SD)

therapeutic use (TU)

toxicity (TO)

urine (UR)

Concept UI: M0024534
Related Numbers: 4097-22-7
Scope Note: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is an inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal side effect is nephrotoxicity. In vivo, dideoxyadenosine is rapidly metabolized to DIDANOSINE (ddI) by enzymatic deamination; ddI is then converted to dideoxyinosine monophosphate and ultimately to dideoxyadenosine triphosphate, the putative active metabolite.
Terms: Dideoxyadenosine Preferred Term
Term UI T047682
Date01/01/1999
LexicalTag NON
ThesaurusID; 2',3'-Dideoxyadenosine
Term UI T047680
Date07/03/1989
LexicalTag NON
ThesaurusID; ddA (Antiviral)
Term UI T047681
Date06/20/1989
LexicalTag NON
ThesaurusID NLM (1990)

Dideoxyadenosine MeSH Descriptor Data 2024